'Five Years of Innovation with Impact' highlights SBC influence on UK biotech sector
Stevenage, UK, September 6 2017 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, is marking its fifth birthday with the launch of an activity review, 'Five Years of Innovation with Impact'. Following developments since 2011, the publication draws a vibrant picture of the UK's first open innovation biomedical campus through figures, case studies and testimonials. The report, which is available on the website, shows how SBC has delivered on its vision of becoming a world-leading hub for life sciences activity.
Highlights of the report include case studies of the University of Cambridge innovation hub at SBC, the open innovation neurodegenerative disease challenge, and cell and gene therapy activities on campus. Companies featured include award-winning Plasticell, inward investor Aglaris and SBC alumnus Avacta Life Sciences.
Also in the report, SBC's founder stakeholders GSK, Wellcome and BEIS/Innovate UK highlight the incubator's impact.
'Since being established five years ago, the Stevenage Bioscience Catalyst and the many scientists involved have created a vibrant scientific community at Stevenage, which has been a key part of a growing open innovation network.', according to GSK.
'Stevenage Bioscience Catalyst offers the collaborative environment essential for innovator-entrepreneurs to transform discoveries into treatments and products to improve our lives.', Wellcome notes.
'Stevenage Bioscience Catalyst has proven to be an exciting scientific and commercially successful world class open innovation pharma campus.', says Innovate UK.
Ian Tomlinson, Independent Chairman of SBC, said, 'With its diverse range of case studies and comment, 'Five Years of Innovation with Impact' highlights the ways in which SBC has worked to catalyse innovation in the UK. In delivering on the vision of our stakeholders, whom we thank for their invaluable support, SBC has created a strong platform and community from which we will continue to collaborate to improve healthcare. The announcement last week of £12m of Government funding for increased capacity at the Cell and Gene Therapy Catapult Manufacturing Centre also recognises the potential of the campus and will be an important driver of its future growth.'
